576 related articles for article (PubMed ID: 30150398)
1. Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption.
Arvanitis CD; Askoxylakis V; Guo Y; Datta M; Kloepper J; Ferraro GB; Bernabeu MO; Fukumura D; McDannold N; Jain RK
Proc Natl Acad Sci U S A; 2018 Sep; 115(37):E8717-E8726. PubMed ID: 30150398
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of permeability, doxorubicin delivery, and drug retention in a rat brain tumor model after ultrasound-induced blood-tumor barrier disruption.
Park J; Aryal M; Vykhodtseva N; Zhang YZ; McDannold N
J Control Release; 2017 Mar; 250():77-85. PubMed ID: 27742444
[TBL] [Abstract][Full Text] [Related]
3. Enhancement in blood-tumor barrier permeability and delivery of liposomal doxorubicin using focused ultrasound and microbubbles: evaluation during tumor progression in a rat glioma model.
Aryal M; Park J; Vykhodtseva N; Zhang YZ; McDannold N
Phys Med Biol; 2015 Mar; 60(6):2511-27. PubMed ID: 25746014
[TBL] [Abstract][Full Text] [Related]
4. Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model.
Park EJ; Zhang YZ; Vykhodtseva N; McDannold N
J Control Release; 2012 Nov; 163(3):277-84. PubMed ID: 23000189
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption.
Kobus T; Zervantonakis IK; Zhang Y; McDannold NJ
J Control Release; 2016 Sep; 238():281-288. PubMed ID: 27496633
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.
Lewis Phillips GD; Nishimura MC; Lacap JA; Kharbanda S; Mai E; Tien J; Malesky K; Williams SP; Marik J; Phillips HS
Breast Cancer Res Treat; 2017 Aug; 164(3):581-591. PubMed ID: 28493046
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.
Lockman PR; Mittapalli RK; Taskar KS; Rudraraju V; Gril B; Bohn KA; Adkins CE; Roberts A; Thorsheim HR; Gaasch JA; Huang S; Palmieri D; Steeg PS; Smith QR
Clin Cancer Res; 2010 Dec; 16(23):5664-78. PubMed ID: 20829328
[TBL] [Abstract][Full Text] [Related]
9. A review of potential applications of MR-guided focused ultrasound for targeting brain tumor therapy.
Lamsam L; Johnson E; Connolly ID; Wintermark M; Hayden Gephart M
Neurosurg Focus; 2018 Feb; 44(2):E10. PubMed ID: 29385922
[TBL] [Abstract][Full Text] [Related]
10. Enhanced delivery of paclitaxel liposomes using focused ultrasound with microbubbles for treating nude mice bearing intracranial glioblastoma xenografts.
Shen Y; Pi Z; Yan F; Yeh CK; Zeng X; Diao X; Hu Y; Chen S; Chen X; Zheng H
Int J Nanomedicine; 2017; 12():5613-5629. PubMed ID: 28848341
[TBL] [Abstract][Full Text] [Related]
11. Multiple treatments with liposomal doxorubicin and ultrasound-induced disruption of blood-tumor and blood-brain barriers improve outcomes in a rat glioma model.
Aryal M; Vykhodtseva N; Zhang YZ; Park J; McDannold N
J Control Release; 2013 Jul; 169(1-2):103-11. PubMed ID: 23603615
[TBL] [Abstract][Full Text] [Related]
12. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
13. Short-time focused ultrasound hyperthermia enhances liposomal doxorubicin delivery and antitumor efficacy for brain metastasis of breast cancer.
Wu SK; Chiang CF; Hsu YH; Lin TH; Liou HC; Fu WM; Lin WL
Int J Nanomedicine; 2014; 9():4485-94. PubMed ID: 25278753
[TBL] [Abstract][Full Text] [Related]
14. Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study.
Aryal M; Vykhodtseva N; Zhang YZ; McDannold N
J Control Release; 2015 Apr; 204():60-9. PubMed ID: 25724272
[TBL] [Abstract][Full Text] [Related]
15. An advanced focused ultrasound protocol improves the blood-brain barrier permeability and doxorubicin delivery into the rat brain.
Jung B; Huh H; Lee EH; Han M; Park J
J Control Release; 2019 Dec; 315():55-64. PubMed ID: 31669208
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticles Containing a Combination of a Drug and an Antibody for the Treatment of Breast Cancer Brain Metastases.
Wyatt EA; Davis ME
Mol Pharm; 2020 Feb; 17(2):717-721. PubMed ID: 31916770
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of doxorubicin in glioblastoma multiforme following ultrasound-Induced blood-brain barrier disruption as determined by microdialysis.
Lin YL; Wu MT; Yang FY
J Pharm Biomed Anal; 2018 Feb; 149():482-487. PubMed ID: 29175555
[TBL] [Abstract][Full Text] [Related]
18. Closed-loop trans-skull ultrasound hyperthermia leads to improved drug delivery from thermosensitive drugs and promotes changes in vascular transport dynamics in brain tumors.
Kim C; Guo Y; Velalopoulou A; Leisen J; Motamarry A; Ramajayam K; Aryal M; Haemmerich D; Arvanitis CD
Theranostics; 2021; 11(15):7276-7293. PubMed ID: 34158850
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment.
Baker JHE; Kyle AH; Reinsberg SA; Moosvi F; Patrick HM; Cran J; Saatchi K; Häfeli U; Minchinton AI
Clin Exp Metastasis; 2018 Oct; 35(7):691-705. PubMed ID: 30196384
[TBL] [Abstract][Full Text] [Related]
20. Brainstem blood brain barrier disruption using focused ultrasound: A demonstration of feasibility and enhanced doxorubicin delivery.
Alli S; Figueiredo CA; Golbourn B; Sabha N; Wu MY; Bondoc A; Luck A; Coluccia D; Maslink C; Smith C; Wurdak H; Hynynen K; O'Reilly M; Rutka JT
J Control Release; 2018 Jul; 281():29-41. PubMed ID: 29753957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
